Professor Song Li, MD, PhD has received a grant from the National Cancer Institute (NCI) for his study titled Targeted Combination Therapy for Breast Cancer. The goal of this five year study is to develop a dual functional drug carrier to achieve synergistic antitumor activity with codelivered anticancer agents to improve the treatment of breast cancer. Song Li is a faculty member at the School of Pharmacy department of pharmaceutical sciences, center for pharmacogenetics.
